Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 8, 2008, Pages 575-583

  Fagioli, Franca ^a   Zecca, Marco ^b   Locatelli, Franco ^b   Lanino, Edoardo ^c   Uderzo, Cornelio ^d   Di Bartolomeo, Paolo ^e   Berger, J Massimo ^a   Favre, Claudio ^f   Rondelli, Roberto ^g   Pession, Andrea ^g   Messina, Chiara ^h  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e Ospedale di Pescara   (Italy)

^f Clinica Pediatrica I   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation; AML in second CR; Leukemia relapse; Pediatric patients

Indexed keywords

ACICLOVIR; AMPHOTERICIN; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; NYSTATIN; STEROID; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLEEDING; BLOOD; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHRONIC GRAFT REJECTION; DONOR; DONOR SELECTION; FAMILY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYCOSIS; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SCHOOL CHILD; STEM CELL; TREATMENT FAILURE; UMBILICAL CORD BLOOD; VIRUS INFECTION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INFANT; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; ONSET AGE; REMISSION; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE;

ADOLESCENT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 53749093669     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31816e2342     Document Type: Article

References (39)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. N Engl J Med. 1994;331:896-903.
3. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood.1996;87:1710- 1717.
4. Woods WG, Kobrinsky N, Buckley JD, et al. Timed sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood.1996;87:4979-4989.
5. Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19:2043-2053.
6. Locatelli F, Labopin M, Ortega J, et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood. 2003;101:16-19.
7. Bonetti F, Zecca M, Pession A, et al. Total body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol. 1999;17: 3729-3735.
8. Dini G, Boni L, Abla OF, et al. Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1994;13:771-776.
9. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7:1071-1080.
10. Davis CL, Rohatiner AZ, Lim J, et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Hematology. 1993;83:404-411.
11. Vignetti M, Orsini E, Petti MC, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol. 1996;7:933-938.
12. Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13-19.
13. Fleischhack G, Hasan C, Graf N, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102:647-655.
14. Webb DK, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia.1999;13:25-31.
15. Godder K, Eapen M, Laver JH, et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol. 2004;22:3798-3804.
16. Aladjidi N, Auvrignon A, Leblanc T, et al. French Society of Pediatric Hematology and Immunology. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377-4385.
17. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord group analysis. Blood. 2003;102:4290-4297.
18. Nemecek ER, Gooley TA, Woolfrey AE, et al. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukaemia. Bone Marrow Transplant. 2004;34: 799-806.
19. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral blood transplantation compared with bone marrow in children and adolescents: the histocompatibility and alternate stem cell source committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872-4880.
20. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75: 555-562.
21. Kolb HJ, Schimidt C, Barrett J, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
22. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
23. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer Clinical Trials: Methods and Practice. Oxford, UK: Oxford Medical Publications; 1988: 423-443.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34:187-202.
26. Klein JP, Rizzo JD, Zhang M-J, et al. Statistical methods for analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28: 909-915.
27. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
28. Klein JP, Rizzo JD, Zhang M-J, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant. 2001;28: 1001-1011.
29. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106:447-453.
30. Mandelli F, Labopin M, Granena A, et al. European survey of bone marrow transplantation in acute promyelocytic leukaemia. Working party on acute leukemia of the European cooperative group for bone marrow transplantation (EBMT). Bone Marrow Transplant.1994;14:293-298.
31. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood. 1995;86:3247-3256.
32. Davies SM, Wagner JE, Shu XO, et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol. 1997;15:557-565.
33. Dini G, Lanino E, Lamparelli T, et al. Unrelated donor marrow transplantation initial experience of the Italian bone marrow transplant group (GITMO). Bone Marrow Transplant. 1996;17: 55-62.
34. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood.2000;95:1572-1579.
35. Stahnke K, Boos J, Bender-Götze C, et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12: 1534-1538.
36. Martinez-Climent JA, Lane NJ, Rubin CM. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995;9:95-101.
37. Wheatley K, Burnett AK, Goldstone AH, et al. on behalf of the United Kingdom Medical Research Concil Adult and Children's Leukemia Working Parties. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from the MRC AML 10 trial. Br J Haematol. 1999;107:69-79.
38. Zecca M, Prete A, Rondelli R, et al. Chronic graft versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;100:1192-1200.
39. Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004;103:3655-3661.